Marine Natural Products and Their Translational Applications in Medicine

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (31 July 2018) | Viewed by 13350

Special Issue Editors

School of Science, Technology and Engineering, University of the Sunshine Coast, Maroochydore, QLD 4558, Australia
Interests: microbial ecology and diversity; microbial systematics; biodiscovery; microbial biotechnology applied; environmental and industrial microbiology; marine microbiology; biological control; actinomycetology; bacteriophages
Special Issues, Collections and Topics in MDPI journals
Department of Pharmacognosy, University of Vienna, Vienna, Austria
Interests: antibiotics; bioprospecting; secondary metabolites biosynthesis; bacterial genetics; metabolic engineering; synthetic biology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Since the 1960s, marine environments have provided a diverse range of naturally-produced compounds, and, notably, those from marine organisms have been shown to display a variety of biological activities with the potential to be utilized for biotechnological, pharmaceutical, cosmetic and environmental applications. Although there are over 15,000 marine natural products described to date, relatively few of these compounds have made it to clinical trials, let alone received approval by the US Food and Drug Administration (FDA) or the European Agency for the Evaluation of Medicinal Products (EMEA) for marketing. As a result, a translational approach that brings different contributors of biomedical research together might reveal the true potential of marine derived compounds, especially for medicinal applications. The latter is of outmost importance considering the looming crisis of antibiotic resistance and the increasing incidence of cancer. In this Special Issue, the Guest Editors would like to invite marine biodiscovery researchers to contribute a variety of manuscripts that will complement others to provide a comprehensive view of a holistic approach to marine biodiscovery. Manuscripts ranging from search and discovery to marine natural product chemistry to clinical applications of marine natural products are invited.

Dr. Ipek Kurtboke
Prof. Dr. Sergey B. Zotchev
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Marine microorganisms

  • translational applications

  • marine biodiscovery

  • marine biotechnology

  • marine environments

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

23 pages, 3215 KiB  
Article
Targeting Hepatic Protein Carbonylation and Oxidative Stress Occurring on Diet-Induced Metabolic Diseases through the Supplementation with Fish Oils
by Silvia Muñoz, Lucía Méndez, Gabriel Dasilva, Josep Lluís Torres, Sara Ramos-Romero, Marta Romeu, María Rosa Nogués and Isabel Medina
Mar. Drugs 2018, 16(10), 353; https://doi.org/10.3390/md16100353 - 26 Sep 2018
Cited by 20 | Viewed by 3757
Abstract
The present study addressed the ability of long-chain ω-3 polyunsaturated fatty acids (ω-3 PUFA), i.e., eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), to ameliorate liver protein damage derived from oxidative stress and induced by consumption of high-caloric diets, typical of Westernized countries. The [...] Read more.
The present study addressed the ability of long-chain ω-3 polyunsaturated fatty acids (ω-3 PUFA), i.e., eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), to ameliorate liver protein damage derived from oxidative stress and induced by consumption of high-caloric diets, typical of Westernized countries. The experimental design included an animal model of Sprague-Dawley rats fed high-fat high-sucrose (HFHS) diet supplemented with ω-3 EPA and DHA for a complete hepatic proteome analysis to map carbonylated proteins involved in specific metabolic pathways. Results showed that the intake of marine ω-3 PUFA through diet significantly decreased liver protein carbonylation caused by long-term HFHS consumption and increased antioxidant system. Fish oil modulated the carbonylation level of more than twenty liver proteins involved in critical metabolic pathways, including lipid metabolism (e.g., albumin), carbohydrate metabolism (e.g., pyruvate carboxylase), detoxification process (e.g., aldehyde dehydrogenase 2), urea cycle (e.g., carbamoyl-phosphate synthase), cytoskeleton dynamics (e.g., actin), or response to oxidative stress (e.g., catalase) among others, which might be under the control of diet marine ω-3 PUFA. In parallel, fish oil significantly changed the liver fatty acid profile given by the HFHS diet, resulting in a more anti-inflammatory phenotype. In conclusion, the present study highlights the significance of marine ω-3 PUFA intake for the health of rats fed a Westernized diet by describing several key metabolic pathways which are protected in liver. Full article
Show Figures

Figure 1

11 pages, 3390 KiB  
Article
Bacillamidins A–G from a Marine-Derived Bacillus pumilus
by Si-Yu Zhou, Yi-Jie Hu, Fan-Cheng Meng, Shen-Yue Qu, Rui Wang, Raymond J. Andersen, Zhi-Hua Liao and Min Chen
Mar. Drugs 2018, 16(9), 326; https://doi.org/10.3390/md16090326 - 11 Sep 2018
Cited by 8 | Viewed by 3414
Abstract
Seven long-chain amides, including five previously undescribed bacillamidins A–E (15) and two previously reported synthetic analogs, bacillamidins F (6) and G (7), were isolated from extracts of the marine-derived Bacillus pumilus strain RJA1515. The structures [...] Read more.
Seven long-chain amides, including five previously undescribed bacillamidins A–E (15) and two previously reported synthetic analogs, bacillamidins F (6) and G (7), were isolated from extracts of the marine-derived Bacillus pumilus strain RJA1515. The structures of the new compounds were established by extensive analysis of 1D and 2D nuclear magnetic resonance (NMR) data as well as high resolution mass spectrometry (HRMS), and the absolute configurations of the stereogenic carbons of 14 were established by comparison of the calculated and the experimental electronic circular dichroism (ECD) spectra. The cytotoxic and antimicrobial activities of 17 were evaluated. Full article
Show Figures

Figure 1

9 pages, 2447 KiB  
Article
Suppression of RANKL-Induced Osteoclastogenesis by the Metabolites from the Marine Fungus Aspergillus flocculosus Isolated from a Sponge Stylissa sp.
by Hee Jae Shin, Byeoung-Kyu Choi, Phan Thi Hoai Trinh, Hwa-Sun Lee, Jong Soon Kang, Tran Thi Thanh Van, Hyi-Seung Lee, Jong Seok Lee, Yeon-Ju Lee and Jihoon Lee
Mar. Drugs 2018, 16(1), 14; https://doi.org/10.3390/md16010014 - 05 Jan 2018
Cited by 26 | Viewed by 5111
Abstract
A new α-pyrone merosesquiterpenoid possessing an angular tetracyclic carbon skeleton, ochraceopone F (1), and four known secondary metabolites, aspertetranone D (2), cycloechinulin (3), wasabidienone E (4), and mactanamide (5), were isolated from the [...] Read more.
A new α-pyrone merosesquiterpenoid possessing an angular tetracyclic carbon skeleton, ochraceopone F (1), and four known secondary metabolites, aspertetranone D (2), cycloechinulin (3), wasabidienone E (4), and mactanamide (5), were isolated from the marine fungus Aspergillus flocculosus derived from a sponge Stylissa sp. collected in Vietnam. The structures of Compounds 15 were elucidated by analysis of 1D and 2D NMR spectra and MS data. All the isolated compounds were evaluated for anti-proliferation activity and their suppression effects on receptor activator of nuclear factor κB ligand (RANKL)-induced osteoclast differentiation using tartate-resisant acid phosphatase (TRAP). Compounds 15 had no anti-proliferative effect on human cancer cell lines up to 30 μg/mL. Among these compounds, aspertetranone D (2) and wasabidienone E (4) exhibited weak osteoclast differentiation inhibitory activity at 10 μg/mL. However, mactanamide (5) showed a potent suppression effect of osteoclast differentiation without any evidence of cytotoxicity. Full article
Show Figures

Graphical abstract

Back to TopTop